15th Apr 2021 10:58
(Alliance News) - GlaxoSmithKline PLC late Wednesday said it has decided to stop enrolling patients in the phase II Induce-3 trial, including discontinuing treatment with feladilimab.
The move follows a recommendation by the Independent Data Monitoring Committee. The Induce-3 study is investigating feladilimab in combination with pembrolizumab versus placebo in combination with pembrolizumab in patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.
The Brentford, England-based Brentford said it also has decided to stop the Induce-4 phase II trial, a study investigating feladilimab versus placebo in combination with pembrolizumab and chemotherapy.
The Induce-3 and Induce-4 studies are being conducted under an agreement between GSK and the US's Merck & Co Inc.
GSK shares were trading 1.5% lower in London on Thursday at 1,270.00 pence each. Merck & Co shares closed marginally lower in New York on Wednesday at USD76.40 each.
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline